BridgeMD
New treatment option for Chronic Kidney Diseases
Official title Sit Less, Interact and Move More (SLIMM) 2 Study
ClinicalTrials.gov ID: NCT05173714
What this study is testing
What is Semaglutide?
Semaglutide is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for chronic kidney diseases.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older
You may be able to join if
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
- Able to perform resistance training
- Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop
You likely can't join if
- Type 1 Diabetes
- History of gastroparesis or paralytic ileus
- At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
- Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2...
- Previous bariatric surgery
- Medical condition likely to limit survival to less than 1 year
See the full eligibility criteria
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
- Able to perform resistance training
- Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop
- Type 1 Diabetes
- History of gastroparesis or paralytic ileus
- At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
- Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
- Previous bariatric surgery
- Medical condition likely to limit survival to less than 1 year
- Anticipated start of dialysis or kidney transplantation within 6 months
- Any factors judged by the investigator or study team to likely limit adherence to interventions
- Vulnerable populations- pregnant or incarcerated
- Enrolled in treatment trials using drugs or devices
- Not able to undergo informed consent
- Recent hospitalizations or major treatment procedures done within the past 60 days
- Known or suspected hypersensitivity to tegaderm
- Use of any GLP-1 receptor agonist within 30 days prior to screening
- Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
- Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
- Presence of metastatic cancer
- Current use of mobility aid(s)
- Living in the same household of a participant already enrolled in the study
The study team makes the final eligibility decision.
Where it's taking place
- Stanford, California, United States
- Salt Lake City, Utah, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Stanford, California, United States; Salt Lake City, Utah, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.